IL-2 Program Profits with Bonum's Drs. John Mulligan and Neela Patel

Business Of Biotech

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, which was fueled by a high-profile asset sale to Roche. The asset, a PD-1-regulated IL-2 program, was a product of a platform that the new Bonum retains, and its sale to Roche was orchestrated by Dr. Patel. You've seen the terms of the deal in the news, but on this episode, you'll get the inside scoop on how the deal was done, how it set Bonum up for future paltform-driven succes, and how these two leaders retained its IP and its people through a fast, unique, and disruptive acquisition.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Kapitel

1. Biotech Business and Good Therapeutics Acquisition (00:00:00)

2. Biotech Deal Making and Business Development (00:08:59)

3. Key Factors in the Acquisition Deal (00:21:37)

4. Transition and Funding of Bonham Therapeutics (00:38:09)

5. Company Growth and Collaboration Strategies (00:50:19)

6. Mentoring and Excitement at Bonham Therapeutics (01:02:54)